These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review. Recharla N; Geesala R; Shi XZ Nutrients; 2023 May; 15(10):. PubMed ID: 37242159 [No Abstract] [Full Text] [Related]
3. Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease. Li G; Lin J; Zhang C; Gao H; Lu H; Gao X; Zhu R; Li Z; Li M; Liu Z Gut Microbes; 2021; 13(1):1968257. PubMed ID: 34494943 [TBL] [Abstract][Full Text] [Related]
4. Intestinal Inflammation Modulates the Epithelial Response to Butyrate in Patients With Inflammatory Bowel Disease. Ferrer-Picón E; Dotti I; Corraliza AM; Mayorgas A; Esteller M; Perales JC; Ricart E; Masamunt MC; Carrasco A; Tristán E; Esteve M; Salas A Inflamm Bowel Dis; 2020 Jan; 26(1):43-55. PubMed ID: 31211831 [TBL] [Abstract][Full Text] [Related]
5. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Parada Venegas D; De la Fuente MK; Landskron G; González MJ; Quera R; Dijkstra G; Harmsen HJM; Faber KN; Hermoso MA Front Immunol; 2019; 10():277. PubMed ID: 30915065 [TBL] [Abstract][Full Text] [Related]
6. Systematic Review and Meta-analysis: Short-Chain Fatty Acid Characterization in Patients With Inflammatory Bowel Disease. Zhuang X; Li T; Li M; Huang S; Qiu Y; Feng R; Zhang S; Chen M; Xiong L; Zeng Z Inflamm Bowel Dis; 2019 Oct; 25(11):1751-1763. PubMed ID: 31498864 [TBL] [Abstract][Full Text] [Related]
7. Butyrate Ameliorates Insufficient Sleep-Induced Intestinal Mucosal Damage in Humans and Mice. Gao T; Wang Z; Dong Y; Cao J; Chen Y Microbiol Spectr; 2023 Feb; 11(1):e0200022. PubMed ID: 36541814 [TBL] [Abstract][Full Text] [Related]
9. Mucin O-glycans facilitate symbiosynthesis to maintain gut immune homeostasis. Yamada T; Hino S; Iijima H; Genda T; Aoki R; Nagata R; Han KH; Hirota M; Kinashi Y; Oguchi H; Suda W; Furusawa Y; Fujimura Y; Kunisawa J; Hattori M; Fukushima M; Morita T; Hase K EBioMedicine; 2019 Oct; 48():513-525. PubMed ID: 31521614 [TBL] [Abstract][Full Text] [Related]
10. A Cross-Talk Between Microbiota-Derived Short-Chain Fatty Acids and the Host Mucosal Immune System Regulates Intestinal Homeostasis and Inflammatory Bowel Disease. Gonçalves P; Araújo JR; Di Santo JP Inflamm Bowel Dis; 2018 Feb; 24(3):558-572. PubMed ID: 29462379 [TBL] [Abstract][Full Text] [Related]
11. Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Thibault R; Blachier F; Darcy-Vrillon B; de Coppet P; Bourreille A; Segain JP Inflamm Bowel Dis; 2010 Apr; 16(4):684-95. PubMed ID: 19774643 [TBL] [Abstract][Full Text] [Related]
12. Butyrate regulates the expression of pathogen-triggered IL-8 in intestinal epithelia. Weng M; Walker WA; Sanderson IR Pediatr Res; 2007 Nov; 62(5):542-6. PubMed ID: 17805211 [TBL] [Abstract][Full Text] [Related]
13. Dietary resistant starch and chronic inflammatory bowel diseases. Jacobasch G; Schmiedl D; Kruschewski M; Schmehl K Int J Colorectal Dis; 1999 Nov; 14(4-5):201-11. PubMed ID: 10647628 [TBL] [Abstract][Full Text] [Related]
14. Inflammatory bowel disease is associated with increased gut-to-blood penetration of short-chain fatty acids: A new, non-invasive marker of a functional intestinal lesion. Jaworska K; Konop M; Bielinska K; Hutsch T; Dziekiewicz M; Banaszkiewicz A; Ufnal M Exp Physiol; 2019 Aug; 104(8):1226-1236. PubMed ID: 31243807 [TBL] [Abstract][Full Text] [Related]
15. Butyrate-producing bacteria supplemented in vitro to Crohn's disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity. Geirnaert A; Calatayud M; Grootaert C; Laukens D; Devriese S; Smagghe G; De Vos M; Boon N; Van de Wiele T Sci Rep; 2017 Sep; 7(1):11450. PubMed ID: 28904372 [TBL] [Abstract][Full Text] [Related]
16. Short Chain Fatty Acids: Essential Weapons of Traditional Medicine in Treating Inflammatory Bowel Disease. Yao Y; Liu Y; Xu Q; Mao L Molecules; 2024 Jan; 29(2):. PubMed ID: 38257292 [TBL] [Abstract][Full Text] [Related]
17. Short chain fatty acids and its producing organisms: An overlooked therapy for IBD? Deleu S; Machiels K; Raes J; Verbeke K; Vermeire S EBioMedicine; 2021 Apr; 66():103293. PubMed ID: 33813134 [TBL] [Abstract][Full Text] [Related]
18. An Engineered Butyrate-Derived Polymer Nanoplatform as a Mucosa-Healing Enhancer Potentiates the Therapeutic Effect of Magnolol in Inflammatory Bowel Disease. Fan X; Zhang Z; Gao W; Pan Q; Luo K; He B; Pu Y ACS Nano; 2024 Jan; 18(1):229-244. PubMed ID: 38112525 [TBL] [Abstract][Full Text] [Related]
19. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Facchin S; Vitulo N; Calgaro M; Buda A; Romualdi C; Pohl D; Perini B; Lorenzon G; Marinelli C; D'Incà R; Sturniolo GC; Savarino EV Neurogastroenterol Motil; 2020 Oct; 32(10):e13914. PubMed ID: 32476236 [TBL] [Abstract][Full Text] [Related]
20. Influence of intestinal inflammation (IBD) and small and large bowel length on fecal short-chain fatty acids and lactate. Hove H; Mortensen PB Dig Dis Sci; 1995 Jun; 40(6):1372-80. PubMed ID: 7781463 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]